Verastem Oncology Plans Public Offering of Common Stock for Commercial Activities and R&D

Verastem Oncology plans to offer common stock in an underwritten public offering, with net proceeds to fund commercial activities, clinical research and development, and general corporate purposes. Jefferies, Guggenheim Securities, and Cantor are acting as joint book-running managers for the proposed offering. A shelf registration statement has been declared effective by the SEC.